Every week we review the most recent publications in women’s mental health, covering topics related to premenstrual symptoms, perinatal mood and anxiety disorders, use of medications in pregnant and breastfeeding women, perinatal substance use, and menopausal mental health.
For more detailed descriptions of many of these topics, you can sign up to receive our weekly CWMH NEWSLETTER which comes out every Thursday.
And don’t forget to visit ESSENTIAL READS – a curated selection of up-to-date and clinically relevant articles in women’s mental health.
Ruta Nonacs, MD PhD
PMS AND PMDD |
| No articles this week
|
INFERTILITY AND MENTAL HEALTH |
| No articles this week
|
PSYCHIATRIC ILLNESS DURING PREGNANCY |
| The effect of antenatal depression and antidepressant treatment on placental tissue: a protein-validated gene expression study.
Edvinsson Å, Hellgren C, Kunovac Kallak T, Åkerud H, Skalkidou A, Stener-Victorin E, Fornes R, Spigset O, Lager S, Olivier J, Sundström-Poromaa I. BMC Pregnancy Childbirth. 2019 Dec 5;19(1):479. Free article. This study compared placental gene and protein expression in healthy women, women with untreated antenatal depression and women on antidepressant treatment during pregnancy. Nominally significant findings were noted for HTR1A (which codes for G-protein coupled receptor for serotonin)and NPY2R (which codes for a neuropeptide Y receptor), where women with untreated depression displayed higher gene expression than healthy controls (p < 0.05), whereas women on antidepressant treatment had similar expression as healthy controls. Missler M, Donker T, Beijers R, Ciharova M, Moyse C, de Vries R, Denissen J, van Straten A. BMC Pregnancy Childbirth. 2021 Apr 1;21(1):276. Free article. Overall, ten studies included depression as an outcome measure, five studies included stress, and four studies anxiety. There was a moderate effect of preventive interventions implemented during pregnancy on the combined measure of maternal distress (d = .52), on depressive symptoms (d = .50), and on stress (d = .52). The effect on anxiety (d = .30) was smaller. Miller-Graff L, et al. J Affect Disord, May 2021. Social support was directly related to lower levels of depressed mood and posttraumatic stress in IPV-exposed women.
|
MEDICATIONS AND PREGNANCY |
| No articles this week
|
POSTPARTUM PSYCHIATRIC ILLNESS |
| The effect of ketamine on preventing postpartum depression.
Alipoor M, Loripoor M, Kazemi M, Farahbakhsh F, Sarkoohi A. J Med Life. 2021 Jan-Mar;14(1):87-92. Free article. Depressive symptoms were lower in women who received ketamine in the induction of general anesthesia at the time of Caesarean section vs. those not receiving ketamine. Shovers SM, Bachman SS, Popek L, Turchi RM. Curr Opin Pediatr. 2021 Mar 31. Prevalence rates of PPD increase to 40% for mothers whose infant is admitted to the NICU.
|
MEDICATIONS AND BREASTFEEDING |
| No articles this week
|
PERINATAL SUBSTANCE USE |
| No articles this week
|
MATERNAL MENTAL HEALTH AND CHILD OUTCOMES |
| Maternal Perinatal Depression and Child Executive Function: A Systematic Review and Meta-Analysis.
Power J, et al. J Affect Disord, May 2021. Poorer executive function outcomes have been identified in the children of depressed mothers and this may represent foundational deficits underlying future dysfunction. Daundasekaraa SS, et al. J Affect Disord, July 2021. Parenting stress mediated the association between maternal hardship and maternal depression and generalized anxiety. Berry OO, et al. J Affect Disord, July 2021. Using a mother-infant dyadic intervention is efficacious in preventing perinatal depression. Women with a history of childhood maltreatment versus those without had limited response to this intervention in terms of preventing perinatal depression yet still reported an increase in infant daytime sleep. Maternal depression during pregnancy alters infant subcortical and midbrain volumes. Sethnaa V, et al. J Affect Disord, May 2021. Maternal major depressive disorder in pregnancy is associated with alterations in infant brain anatomy in early life. Infants exposed to depression had significantly larger subcortical grey matter volumes and smaller midbrain volumes.
|
MENOPAUSE AND MENTAL HEALTH |
| Prescription medications for sleep disturbances among midlife women during 2 years of follow-up: a SWAN retrospective cohort study.
Solomon DH, et al. BMJ Open 2021;11:e045074. Women who initiated sleep medications rated their sleep disturbances similar after 1 and 2?years of treatment. Cheng YS, Tseng PT, Wu MK, Tu YK, Wu YC, Li DJ, Chen TY, Su KP, Stubbs B, Carvalho AF, Lin PY, Matsuoka YJ, Chen YW, Sun CK, Shiue YL. Sleep Med Rev. 2021 Mar 11;57:101469. The results support combined estrogen-progesterone therapy for menopausal sleep disturbances associated with vasomotor symptoms but showed no significant effects of hypnotics in this clinical setting. Schmidt PJ, Wei SM, Martinez PE, Dor RRB, Guerrieri GM, Palladino PP, Harsh VL, Li HJ, Wakim P, Nieman LK, Rubinow DR. Menopause. 2021 Jan 15;28(4):369-383. This study did not identify significant therapeutic benefits of transdermal estradiol, the phytoestrogen Rimostil, or raloxifene compared with placebo in perimenopausal depression.
|
OTHER TOPICS IN WOMEN’S MENTAL HEALTH |
| No articles this week |
Leave A Comment